Ocular Therapeutix Inc/ US67576A1007 /
2024-04-23 10:00:00 PM | Chg. -0.0750 | Volume | Bid1:02:03 AM | Ask1:02:03 AM | High | Low |
---|---|---|---|---|---|---|
5.0000USD | -1.48% | 2.28 mill. Turnover: 9.82 mill. |
5.0000Bid Size: 800 | 5.0500Ask Size: 500 | 5.1500 | 4.9600 |
GlobeNewswire
04-18
Ocular Therapeutix™ Announces Positive Topline Phase 1 Data for AXPAXLI™ in Diabetic Retinopathy
GlobeNewswire
04-16
Ocular Therapeutix™ Strengthens Clinical Team with Appointment of Key Retinal Leaders
GlobeNewswire
04-15
Ocular Therapeutix™ Executive Chairman Pravin U. Dugel, MD Becomes President and CEO Antony Mattessi...
GlobeNewswire
04-09
Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Senior Vice Pre...
GlobeNewswire
04-06
Ocular Therapeutix™ Announces Positive Phase 2 PAXTRAVA™ Glaucoma Data at the American Society of Ca...
GlobeNewswire
03-26
Ocular Therapeutix™ To Present Data at the 2024 ASCRS Annual Meeting (American Society of Cataract a...
GlobeNewswire
03-05
Ocular Therapeutix™ to Release Fourth Quarter and Full Year 2023 Results on March 11, 2024
GlobeNewswire
02-22
Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed...
GlobeNewswire
02-13
Ocular Therapeutix™ Announces First Subjects Screened in Phase 3 Pivotal Clinical Trial of AXPAXLI™ ...
GlobeNewswire
02-08
Stakes Are High for Regeneron's Eylea HD as Genentech's Vabysmo Continues to Gain Momentum, Promptin...
GlobeNewswire
01-25
Ocular Therapeutix™ Announces FDA Agreement to Amend Special Protocol Assessment (SPA) for Pivotal C...
GlobeNewswire
2023-12-18
Ocular Therapeutix™ Announces Closing of Public Offering of Common Stock and Full Exercise by Underw...
GlobeNewswire
2023-11-07
Ocular Therapeutix™ Provides Third Quarter 2023 Financial Results and Corporate Update
GlobeNewswire
2023-11-01
Ocular Therapeutix™ Receives FDA Agreement Under Special Protocol Assessment (SPA) for its First Piv...
GlobeNewswire
2023-10-03
Ocular Therapeutix™ Announces Initiation of its First Pivotal Clinical Trial of OTX-TKI in Wet AMD